Synfini, Inc., founded in Menlo Park, California, is a pioneering company in agile chemistry. Its core mission is to transform modern drug discovery by integrating neuro-symbolic AI, robotic automation, and advanced molecular platforms. Synfini's innovative platform, which includes automated chemical synthesis technologies from SRI International, aims to accelerate the discovery of novel therapeutics to enhance human health and longevity. The company primarily focuses on providing accelerated molecular discovery services to drug hunters and pharmaceutical researchers.

Notable affiliates include SRI International, from which Synfini spun out. The company has achieved significant milestones, including the development of its patented molecular discovery platform that combines physical and virtual chemistry. Synfini's impact lies in its ability to streamline and expedite the drug discovery process, potentially leading to faster development of new treatments and therapies. This positions Synfini as a transformative player in the pharmaceutical and biotechnology sectors.